Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020)
- 20 April 2022
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 60 (4) , e0244921
Abstract
Rezafungin is a new echinocandin under development for the treatment of candidemia and invasive candidiasis. CLSI recently approved provisional susceptible-only breakpoints and epidemiological cutoff values for Candida spp. and rezafungin. The activities of rezafungin and comparators against 2019 to 2020 invasive fungal isolates was evaluated by applying the new CLSI breakpoints. Rezafungin demonstrated potent activity against Candida albicans (MIC 50 /MIC 90 , 0.03/0.06 mg/L; 100.0% susceptible), Candida tropicalis (MIC 50 /MIC 90 , 0.03/0.06 mg/L; 100% susceptible), Candida glabrata (MIC 50 /MIC 90 , 0.06/0.06 mg/L; 98.3% susceptible), Candida krusei (MIC 50 /MIC 90 , 0.03/0.03 mg/L; 100% susceptible), and Candida dubliniensis (MIC 50 /MIC 90 , 0.06/0.12 mg/L; 100% susceptible) when tested by the CLSI broth microdilution method. Rezafungin inhibited 99.6% of Candida parapsilosis isolates (MIC 50 /MIC 90 , 1/2 mg/L) at the susceptible breakpoint of ≤2 mg/L. All C. albicans , C. tropicalis , and C. krusei isolates, as well as most C. glabrata (96.2% to 97.9%) and C. parapsilosis (86.2% to 100%) isolates, were susceptible to comparator echinocandins. Fluconazole resistance was detected among 0.5%, 4.5%, 10.5%, and 1.2% of C. albicans , C. glabrata , C. parapsilosis , and C. tropicalis isolates, respectively. All echinocandins displayed limited activity against Cryptococcus neoformans . Rezafungin and other echinocandins were active against Aspergillus fumigatus (minimum effective concentration for 90% of isolates tested [MEC 90 ] range, 0.015 to 0.06 mg/L) and Aspergillus section Flavi (MEC 90 range, 0.015 to 0.03 mg/L). All but 16 (8.6%) A. fumigatus isolates were susceptible to voriconazole, and 100% of Aspergillus section Flavi isolates were WT to mold-active azoles. When applying the CLSI clinical breakpoints, rezafungin displayed high susceptibility rates (>98.0%) against Candida isolates from invasive fungal infections and showed potent activity against Aspergillus isolates.Keywords
Funding Information
- Cidara Therapeutics (21-CID-04)
This publication has 25 references indexed in Scilit:
- Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicansAntimicrobial Agents and Chemotherapy, 2017
- Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy AdultsAntimicrobial Agents and Chemotherapy, 2017
- Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel EchinocandinAntimicrobial Agents and Chemotherapy, 2016
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2016
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2015
- International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatusDrug Resistance Updates, 2015
- In Vitro Antifungal Susceptibility of Clinically Relevant Species Belonging to Aspergillus Section FlaviAntimicrobial Agents and Chemotherapy, 2013
- Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance ProgrammeMycopathologia, 2012
- Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasisCritical Care, 2011
- Epidemiology of Invasive Mycoses in North AmericaCritical Reviews in Microbiology, 2010